Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ARID1A-Deficient Tumors Acquire Immunogenic Neoantigens during the Development of Resistance to Targeted Therapy.

Cancer research - 4 Sept 2024

Okada Masahiro, Yamasaki Satoru, Nakazato Hiroshi, Hirahara Yuhya, Ishibashi Takuya, Kawamura Masami, Shimizu Kanako, Fujii Shin-Ichiro

Abstract excerpt

Neoantigen-based immunotherapy is an attractive potential treatment for previously intractable tumors. To effectively broaden the application of this approach, stringent biomarkers are crucial to identify responsive patients. ARID1A, a frequently mutated subunit of SWI/SNF chromatin remodeling complex, has been reported to determine tumor immunogenicity in some cohorts; however, mutations and deletions of ARID1A...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Immunotherapy

Share to Melanoma

Share to Molecular Targeted Therapy

Share to Proto-Oncogene Proteins B-raf

Share to Vemurafenib

Source

Identifiers

PMID: 39228255
DOI: 10.1158/0008-5472.CAN-23-2846

Genes

ARID1A

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ARID1A-Deficient Tumors Acquire Immunogenic Neoantigens during the Development of Resistance to Targeted Therapy.PMID 39228255Read ↗

Comprehensive analysis of multiple parameters associated with tumor immune microenvironment in ARID1A mutant cancers.Semantic proximity Read ↗

Tumor-infiltrating BRAFV600E-specific CD4+ T cells correlated with complete clinical response in melanomaSemantic proximity Read ↗

ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer.Semantic proximity Read ↗

Efficacy of immunotherapy in ARID1A-mutant solid tumors: a single-center retrospective studySemantic proximity Read ↗

ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapySemantic proximity Read ↗

Effect and biomarker of immune checkpoint blockade therapy for ARID1A deficiency cancersSemantic proximity Read ↗

Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy.Semantic proximity Read ↗

Low level of ARID1A contributes to adaptive immune resistance and sensitizes triple‐negative breast cancer to immune checkpoint inhibitorsSemantic proximity Read ↗

ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade.Semantic proximity Read ↗

Somatic ARID1A mutation stratifies patients with gastric cancer to PD-1 blockade and adjuvant chemotherapy.Semantic proximity Read ↗

Pan-cancer analysis of ARID family members as novel biomarkers for immune checkpoint inhibitor therapy.Semantic proximity Read ↗

ARID2 mutations may relay a distinct subset of cutaneous melanoma patients with different outcomes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.